NCT00645307View on ClinicalTrials.gov

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

PHASE3CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

August 31, 2006

Conditions
Schizophrenia
Interventions
DRUG

Extended Release OROS® Paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00645307 - A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. | Biotech Hunter | Biotech Hunter